The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
Reg A+
Biotech
  • Raised
    $1mm+
  • Investors on Seedinvest
    550+
Learn More & Invest

Analysis Summary

Health Score
81
%
Market Size
100
%
Traction
60
%
Team
95
%
Competition
70
%

EPO Independent Analysis

Cytonics is developing an exciting product that meets a significant need in a growing market ($180b currently). The company has a strong executive team and board of advisors, and EPO believes their business model closely matches their core competencies. Preclinical results indicate signs of safety & efficacy, which paves the way to submission for Phase 1 of FDA approval.

As explained in the sections below, there are four key considerations in assessing Cytonics as an investment.

1. 1. The potential market size for CYT-108

2. The risk associated with the FDA trial process


Want the full EPO analysis?

The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.

Developing proprietary and innovative biologic therapies for osteoarthritis.

  • Raised over $15mm to date, including a $4mm investment from Synthes (a Johnson & Johnson company)
  • Executed licensing agreements for sale of its technologies in the human and veterinary markets, with a value up to $7mm
  • Preclinical results indicate signs of safety & efficacy, which paves the way to submission for Phase 1 of FDA approval
  • IP portfolio consists of 8 issued U.S. and international patents with 9 patents pending
  • Clear path to exit through acquisition by big pharma

Cytonics is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from: Cytonics: https://www.seedinvest.com/cytonics